>>> Larry Kudlow CNBC interview

Larry Kudlow CNBC interview
  • Cabinet was not asked by President Trump to draw up trade plan for China -- officially denying Bloomberg report from sources
  • Has already put out demands to China regarding trade.
  • There is no mass moment, not on the cusp of a deal.
  • President Trump's phone call with Xi was positive. Trade will be on the agenda at the G-20.
  • G-20 meeting is definitely going to happen.
  • There is still a chance for additional tariffs; it depends on how talks go.
  • If China makes progress toward demands, tariffs could be removed.
  • Not as optimistic as he was before.
  • Does not want to comment on the Fed's recent rate increases.
  • Middle class tax cut is on the table after the midterms.

>>> CPB US - Third Point (7% stake) responds to Campbell’s latest remarks “We ar

Third Point (7% stake) responds to Campbell’s latest remarks

“We are dismayed that Campbell’s inept Board thinks it is appropriate to mislead shareholders by misrepresenting our plan in an obvious attempt to divert attention from its own track record, which can be simply summarized as zero value created for shareholders in twenty years. The Entrenched Board continues to make the same, debunked claim that the Independent Slate’s only plan is to sell the Company when we have stated clearly that our call for a sale was specific to the strategic review period with this dysfunctional leadership team in place. When the Entrenched Board did not reach this same conclusion during the strategic review and instead decided to muddle along and drive shares down further, we decided to challenge its leadership to benefit all shareholders. Since announcing our proxy plans, we have advanced thoughtful and thorough plans about how the Independent Slate will improve Campbell that are far more substantive than the Company’s plan, which is simply flaccid language about selling a few assets and hiring a CEO, which the Entrenched Board has proved unable to do for nearly six months.Campbell further insults shareholders today by suggesting that it is a “waste of time” for non-insider, non-heir shareholders to expresstheir views about how this company – which stock is down more than 20% in this year alone – can improve. The changes the Entrenched Board claims to have made are too little, too late and a simple stock chart shows the current directors are already failing to create value, just like this Entrenched Board’s previous “strategic plans”.Our 100-day operating plan positions the Independent Slate to expeditiously implement operational, strategic, and financial initiatives that we believe the current Board does not have the expertise, vision, or will to execute.It’s long past time that a qualified, independent Board has an opportunity to execute a thoughtful strategy that can yield better management, improvements across the corporate culture, a modernization of core products, and an enhanced focus on the Company’s legendary Soup brands.”After reviewing our summarized plan here, we encourage shareholders to also review The Independents and Fiction vs. Fact to understand more about why the Independent Slate will respect Shareholder voices, end the Insider Board Members’ Reign of Error, and set Campbell on a new and profitable path. We urge all shareholders to VOTE THE WHITE CARD to elect the Independent Slate. Related ()

>>> US Gapping down


Gapping down
In reaction to disappointing earnings/guidance
:

  • PBYI -35.2%, OLED -26.3%, MDRX -17.8%, WTW -13.1%, GPRO -13.1%, CC -11.1%, ACLS -9.4%, CARB -7.2%, TEX -6.9%, KHC -6.7%, LOCO -6.3%, HYGS -5.8%, AAPL -5.7%, TRMB -5.4%, SHAK -5.1%, EEP -3.5%, BIO -3.4%, ROG -3%, CTRL -2.8%, TDOC -2.2%, CBS -2.1%, RP -1.6%, SRG -1.4%, FTNT -1.1%, SM -1.1%

Other news:

  • ADVM -34.9% (provides program updates; announces decision to discontinue the development of ADVM-043 based on review of the ADVANCE Phase 1/2 study)
  • MVIS -8.2% (files $60 mln mixed securities shelf offering)
  • SYF -7.3% (Synchrony Financial issues statement in response to lawsuit by Walmart (WMT))
  • ALKS -5.7% (confirms outcome from FDA Advisory Committe Meeting on NDA for ALKS 5461 for the adjunctive treatment of major depressive disorder)

Analyst comments:

  • UPS -0.8% (downgraded to Neutral at Citibank)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:

  • EXEL +14.4%, ARCB +14%, ACIA +12.4%, CZR +11.9%, EXTR +10.7%, PETX +10.6%, ANET +10.6%, CATM +9.9%, NWL +9.1%, ERII +8.8%, SYMC +8.6%, SBUX +8.2%, CRC +7.9%, GTE +7.8%, BTE +7.5%, TSRO +7.4%, TTOO +7%, SEDG +6.6%, BLDR +6.6%, BABA +5.9%, STX +5.8%, IPHI +5.3%, TDS +5.3%, PE +5.2%, LADR +4.8%, BRKR +4.6%, MTZ +4.5%, WLTW +4.3%, CCJ +4%, TNDM +3.6%, ABBV +3.6%, SHLX +3.4%, WIFI +3.4%, ITT +3.4%, XOM +3.4%, MET +3.2% (approves new $2 bln common stock repurchase authorization), HST +2.9%, LYV +2.9%, PBA +2.8%, CERS +2.7%, TRQ +2.5%, TRTN +2.5%, IMGN +2.5%, DHT +2.3%, CNK +2.3%, MITK +2.1%, X +2%, EBS +1.9%, HMSY +1.8%, APPN +1.6%, AIRG +1.5%, ESPR +1.1%

Other news:

  • PACB +68.5% (Pacific Biosciences to be acquired by Illumina (ILMN) for $8.00/share in cash, or approximately $1.2 bln)
  • NIHD +7.7% (attributed Brazil's Anatel spectrum update)
  • VRSN +6.9% (after disclosing amendment to Department of Commerce cooperative agreement)
  • RTIX +5% (ticking higher; to acquire Paradigm Spine in cash and stock transaction valued at up to $300 mln)
  • ALGN +4.1% (after announcing resignation of SVP and managing director of the Americas region, Christopher Puco, effective March 2019)
  • CAT +3.1% (following TEX results)
  • BDSI +3.1% (announces further significant expanded preferred coverage for BELBUCA)
  • MFC +3% (announces three reinsurance transactions on its legacy businesses, its intention to launch a Normal Course Issuer Bid and an increase to its common share dividend),
  • GOOS +1.8% (acquires Baffin Inc. for purchase price of CAD $32.5 mln)
  • STRL +0.9% (Sterling Construction unit and jv partner SEMA Construction were selected by Colorado Department of Transportation for $200 mln+ highway project)
  • ILMN +0.8% (Pacific Biosciences to be acquired by Illumina (ILMN) for $8.00/share in cash, or approximately $1.2 bln)
  • GPOR +0.7% (appoints Donnie Moore as Interim CEO, effective immediately)

Analyst comments:

  • KORS +6.3% (upgraded to Overweight from Neutral at Piper Jaffray)
  • WFC +0.8% (upgraded to Buy at Citibank)